Iyoha, Ehiremen M

AbstractSinonasal mucosal melanoma (SNMM) is a rare malignancy with poor prognosis and high recurrence rate. In those with recurrence, survival is dismal. Immunotherapy is an emerging area of investigation; however, there is a scarcity of data on immunotherapy outcomes in SNMM patients with recurrence. We report outcomes of immunotherapy in recurrent SNMM patients with distant versus nondistant recurrence. Fifty‐four patients with recurrent SNMM were identified, and 31 (57.4%) had distant recurrence. One‐year overall survival (OS) following recurrence was 47.5% (95% confidence interval [CI]: 34.0%‐60.9%), with a median survival of 2.8 years (95% CI: 2.0‐5.3). In those with distant recurrence, receipt of immunotherapy was associated with better OS compared to those without immunotherapy (hazard ratio [HR] = 0.29 [95% CI: 0.12‐0.68], P = .004). While patients with nondistant recurrence (n = 23), who received immunotherapy (n = 6) had worse OS compared to those who did not receive immunotherapy (HR = 4.76 [95% CI: 1.36, 15.89], P = .02).Level of EvidenceLevel IV.